Eli Lilly (NYSE: LLY) Acquires Three Vaccine Developers for $3.8 Billion

Eli Lilly and Company announced a $3.8 billion acquisition spree, purchasing three vaccine developers to bolster its immunology pipeline. The deal includes LimmaTech Biologics, acquired to advance next-generation vaccine candidates against common bacterial infections; an unnamed vaccine company focused on Epstein-Barr Virus (EBV) and other infectious diseases; and Curevo, which will support next-generation shingles prevention efforts.

By the Numbers

• Total acquisition value: $3.8 billion
• Primary focus areas: EBV, bacterial infections, shingles prevention
• Stock price: $1,065.00, up 2.24% on Monday, May 25, 2026

Why It Matters

The three acquisitions represent a strategic pivot toward vaccine development and prevention-based therapies—a segment distinct from Eli Lilly's dominant diabetes and obesity drug franchises. By acquiring clinical-stage and preclinical candidates across multiple infectious disease areas, the company is diversifying revenue sources beyond GLP-1 agonists and addressing large unmet needs in viral and bacterial infection prevention.

These deals also signal Eli Lilly's confidence in the vaccine market's growth trajectory and its ability to compete against established players and newer entrants in immunology. The specific focus on EBV and shingles reflects high-burden diseases affecting large patient populations, particularly in aging demographics.

Wall Street View

Analysts tracking Eli Lilly note the company's strong execution track record on integrations and pipeline advancement. The stock trades at a trailing P/E of 37.9x (TTM — may not reflect latest quarter), with a forward P/E of 23.9x, suggesting markets price in continued growth despite the high valuation.

Investor Takeaway

The $3.8 billion vaccine acquisition package extends Eli Lilly's therapeutic reach into prevention-focused areas with significant commercial potential. For long-term holders, these bolt-on deals diversify pipeline risk away from obesity and diabetes. Near-term investors should monitor integration progress and clinical trial readouts for the acquired candidates, particularly EBV vaccine timelines and shingles prevention efficacy data.